Savara Inc.SVRA

$5.50+0.12 (+2.23%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$1B

Small-cap

+4816%

2017 — today

10-Year Price

-41%

2017 — today

52-Week Range

$2.05$6.94

Current $5.50· 71%

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Valuation in context

P/E ratio

-9.8

N/A

Not meaningful — company is unprofitable

P/B ratio

7.9

Near historic high

Near historic highs — last 10 years

FCF Yield

-7.7%

Historically high

Historically high relative to the last 10 years

Free · No credit card needed

Get alerted when SVRA is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.